| Literature DB >> 29773995 |
Diana Braun1,2, Christa Zollbrecht3, Stefanie Dietze1,2, Rudolf Schubert4, Stefan Golz5, Holger Summer5, Pontus B Persson1,2, Mattias Carlström3, Marion Ludwig1,2, Andreas Patzak1,2.
Abstract
Ischemia/reperfusion injury holds a key position in many pathological conditions such as acute kidney injury and in the transition to chronic stages of renal damage. We hypothesized that besides a reported disproportional activation of vasoconstrictor response, hypoxia/reoxygenation (H/R) adversely affects endothelial dilatory systems and impairs relaxation in renal arteries. Rat renal interlobar arteries were studied under isometric conditions. Hypoxia was induced by application of 95% N2, 5% CO2 for 60 min to the bath solution, followed by a 10 min period of reoxygenation (95% O2, 5% CO2). The effect of H/R on relaxation was assessed using various inhibitors of endothelial dilatory systems. mRNA expression of phosphodiesterase 5 (PDE5), NADPH oxidases (NOX), and nitric oxide synthase (NOS) isoforms were determined using qRT-PCR; cGMP was assayed with direct cGMP ELISA. Acetylcholine induced relaxation was impaired after H/R. Inhibition of the NOS isoforms with L-NAME, and cyclooxygenases (COXs) by indomethacin did not abolish the H/R effect. Moreover, blocking the calcium activated potassium channels KCa3.1 and KCa2.1, the main mediators of the endothelium-derived hyperpolarizing factor, with TRAM34 and UCL1684, respectively, showed similar effects in H/R and control. Arterial stiffness did not differ comparing H/R with controls, indicating no impact of H/R on passive vessel properties. Moreover, superoxide was not responsible for the observed H/R effect. Remarkably, H/R attenuated the endothelium-independent relaxation by sodium nitroprusside, suggesting endothelium-independent mechanisms of H/R action. Investigating the signaling downstream of NO revealed significantly decreased cGMP and impaired relaxation during PDE5 inhibition with sildenafil after H/R. Inhibition of PKG, the target of cGMP, did not normalize SNP-induced relaxation following H/R. However, the soluble guanylyl cyclase (sGC) inhibitor ODQ abolished the H/R effect on relaxation. The mRNA expressions of the endothelial and the inducible NOS were reduced. NOX and PDE5 mRNA were similarly expressed in H/R and control. Our results provide new evidence that impaired renal artery relaxation after H/R is due to a dysregulation of sGC leading to decreased cGMP levels. The presented mechanism might contribute to an insufficient renal reperfusion after ischemia and should be considered in its pathophysiology.Entities:
Keywords: cGMP; hypoxia; ischemia/reperfusion injury; nitric oxide; relaxation; sGC; vascular smooth muscle
Year: 2018 PMID: 29773995 PMCID: PMC5943512 DOI: 10.3389/fphys.2018.00480
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Primer for the mRNA expression studies.
| Primer | Forward | Reverse |
|---|---|---|
| nNOS | ATCCAGGTGGACAGAGACCTCGATG | CCGAGGTAGGGGACTGTTCCTTCTCT |
| iNOS | CAGGTGCTATTCCCAGCCCAACA | CATTCTGTGCAGTCCCAGTGAGGAA |
| eNOS | CAGCACCAGACCACAGCCCC | TCCTGCTGAGCCTGTGCACT |
| NOX1 | CGTCACTCCCTTTGCTTCCT | AGGCACCCGTCTCTCTACAA |
| NOX2 | CTGCCAGTGTGTCGGAATCT | ACACACCACTCCACGTTGAA |
| NOX4 | TTGGTGAACGCCCTGAACTT | TACCACCACCATGCAGACAC |
| 18S rRNA | ACGGACCAGAGCGAAAGCAT | TGTCAATCCTGTCCGTGTCC |
| PDE5A | GTCTGCCCAAACCCTTAAAA | CGCTGTTTCCAGATCAGACA |
| RPL32 | GAAAGAGCAGCACAGCTGGC | TCATTCTCTTCGCTGCGTAGC |
EC50 (mean ± SEM) and maximum response (mean ± SEM) of small vessel myograph studies; # indicates P < 0.05.
| Treatment | EC50 control (mol/l) | EC50 hypoxia (mol/l) | Maximum response control (%) | Maximum response hypoxia (%) |
|---|---|---|---|---|
| ACh-CRC | 2.37∗10-7± 3.32∗10-8 | 4.75∗10-7± 6.29+10-8 # | –82.79 ± 3.78 | –75.04 ± 2.77 |
| L-NAME+ACh-CRC | 3.33∗10-7± 4.99∗10-8 | 9.54∗10-7± 2.43∗10-7 # | –62.32 ± 4.86 | –36.22 ± 5.22 # |
| Indo+ACh-CRC | 1.63∗10-7± 3.23∗10-8 | 4.00∗10-7± 6.43∗10-8 # | –87.78 ± 1.92 | –82.06 ± 2.45 |
| TRAM34+ACh-CRC | 2.02∗10-7± 6.08∗10-8 | 4.05∗10-7± 8.00∗10-8 # | –83.66 ± 1.75 | –81.43 ± 2.15 |
| UCL1684+ACh-CRC | 3.52∗10-7± 6.41∗10-8 | 2.07∗10-6± 1.36∗10-6 # | –87.54 ± 4.51 | –76.78 ± 2.77 # |
| L-NAME+Indo+SNP-CRC | 3.32∗10-8± 1.00∗10-8 | 9.37∗10-8± 2.70∗10-8 # | –89.77 ± 1.82 | –86.63 ± 2.45 |
| L-NAME+Indo+Tempol+SNP-CRC | 3.34∗10-8± 6.58∗10-9 | 6.75∗10-8± 1.53∗10-8 # | –86.53 ± 2.02 | –87.02 ± 1.81 |
| Sildenafil-CRC | 1.18∗10-6± 3.00∗10-7 | 7.14∗10-6± 2.51∗10-6 # | –89.69 ± 1.91 | –89.55 ± 1.30 |
| L-NAME+Indo+DT-2+SNP-CRC | 2.14∗10-8± 5.45∗10-9 | 4.88∗10-8± 7.91∗10-9 # | –93.37 ± 1.50 | –93.64 ± 1.78 |
| ODQ+ACh-CRC | 8.90∗10-7± 5.34∗10-7 | 1.70∗10-6± 5.68∗10-7 | –20.76 ± 6.64 | –3.03 ± 5.10 |